Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715

Q2 FY26 results · Jul–Sep 2025

Sun Pharmaceutical Industries reported revenue from operations of ₹14,478.31 crore (up 8.9% from Q2 FY25) and net profit of ₹3,124.95 crore (up 2.9% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY26	Q2 FY25	YoY	Q1 FY26	QoQ
Revenue from operations	14,478.31	13,291.39	+8.9%	13,851.40	+4.5%
Other income	469.92	354.00	+32.7%	464.46	+1.2%
Total income	14,948.23	13,645.39	+9.5%	14,315.86	+4.4%
Profit before share of associates & JVs and tax	4,167.61	3,597.88	+15.8%	3,172.77	+31.4%
Share of profit/(loss) of associates & JVs	(12.14)	6.66		(9.75)
Net profit for the period	3,124.95	3,037.33	+2.9%	2,292.87	+36.3%
Attributable to shareholders of the company	3,117.95	3,040.16	+2.6%	2,278.63	+36.8%
EPS, basic (₹)	13.00	12.70	+2.4%	9.50	+36.8%
Net margin (%)	21.6	22.9		16.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY26	Q2 FY25	YoY	Q1 FY26	QoQ
Revenue from operations	4,548.11	5,127.71	−11.3%	5,601.96	−18.8%
Other income	72.79	86.30	−15.7%	103.69	−29.8%
Total income	4,620.90	5,214.01	−11.4%	5,705.65	−19.0%
Profit before tax	671.75	895.64	−25.0%	1,184.88	−43.3%
Net profit for the period	564.22	863.29	−34.6%	753.53	−25.1%
EPS, basic (₹)	2.40	3.60	−33.3%	3.10	−22.6%
Net margin (%)	12.4	16.8		13.5

Consolidated

Filed with BSE: 05 Nov 2025, 19:07 IST
Board meeting: 05 Nov 2025
Period: 01 Jul 2025 to 30 Sep 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 05 Nov 2025, 19:07 IST
Board meeting: 05 Nov 2025
Period: 01 Jul 2025 to 30 Sep 2025
Review status: Unaudited
Source: XBRL filing on BSE